Boston Therapeutics Ph 2 Study Achieves Full Enrollment
22 août 2019 13h55 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter...
Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia
14 févr. 2019 11h18 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...
Boston Therapeutics Announces Marketing of Sugardown® in Asia
13 déc. 2018 11h13 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia
07 déc. 2018 13h26 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics and Prevail InfoWorks Announce Strategic Clinical Partnership
03 oct. 2018 08h15 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of carbohydrate based...
Boston Therapeutics Initiates New Exploratory and Adaptive Multicenter Clinical Study of BTI320 On Type 2 Diabetics Currently on Metformin and or Sulfonylureas in the United States
24 sept. 2018 11h35 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics Phase IIa Study Results Accepted for Publication
24 août 2018 09h30 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase IIa proof of concept study evaluating the efficacy and safety...
Boston Therapeutics to launch social commerce channel for Sugardown® in China
09 août 2018 11h52 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (“BTI”) (OTCQB:BTHE), a BioPharmaceutical leader in the design, development and commercialization of innovative...
Boston Therapeutics Introduces Sugardown® to the US under kathy Ireland® Health & Wellness
27 juin 2018 12h52 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...
Boston Therapeutics Initiates New Clinical Study of BTI-320
22 mai 2018 12h58 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics...